Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FXS0683 in Relapsed or Refractory Hematologic Malignancies
NCT07616089Phase 1Recruiting
- Sponsor
- Fosun Pharma
- Start
- Jun 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FXS0683 in B cell lymphoma, acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and 1 more, sponsored by Fosun Pharma. Primary endpoints: Dose-Limiting Toxicities at 4 weeks and Maximum Tolerated Dose and/or Recommended Phase 2 Dose at 3 years. Started Jun 2026; status: recruiting.
02
Drugs
FXS0683
03
Conditions
B cell lymphomaacute myeloid leukemia (AML)myelodysplastic syndrome (MDS)acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT07616089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07616089.